Posted by Michael Wonder on 14 Apr 2022
Over 700 people a year could benefit from a new potentially life-extending lung cancer drug which targets a specific genetic mutation
14 April 2022 - An innovative and potentially life-extending drug for treating people with a specific gene mutation of advanced non-small-cell lung cancer has been recommended by NICE and will be available to patients from today.
The drug has been recommended for routine use across the NHS in England through Project Orbis, a programme to review and approve promising cancer drugs helping patients access treatments faster.
